{"id":59421,"date":"2026-03-13T22:00:55","date_gmt":"2026-03-13T14:00:55","guid":{"rendered":"https:\/\/flcube.com\/?p=59421"},"modified":"2026-03-13T22:00:56","modified_gmt":"2026-03-13T14:00:56","slug":"kintor-pharmaceutical-partners-with-fonow-medicine-kt-939-cosmetic-collaboration-targets-china-whitening-and-melasma-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59421","title":{"rendered":"Kintor Pharmaceutical Partners with Fonow Medicine \u2013 KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market"},"content":{"rendered":"\n

Kintor Pharmaceutical Limited<\/strong> (HKG: 9939<\/a>) entered into a strategic cooperation agreement<\/strong> with Zhejiang Fonow Medicine Co., Ltd.<\/strong> to accelerate R&D, registration, and production<\/strong> of functional special-purpose cosmetics<\/strong> containing KT-939 raw material<\/strong>. Under terms, Kintor supplies the active pharmaceutical ingredient and grants Fonow exclusive China rights<\/strong> to develop, manufacture, and market whitening and spot-removing products<\/strong>, complementing Fonow’s core Folimei Cream<\/strong> franchise in the melasma treatment<\/strong> market.<\/p>\n\n\n\n

Partnership Structure<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Parties<\/strong><\/td>Kintor Pharmaceutical (HKG: 9939) + Zhejiang Fonow Medicine Co., Ltd.<\/td><\/tr>
Agreement Type<\/strong><\/td>Strategic cooperation (API supply + product development)<\/td><\/tr>
Core Asset<\/strong><\/td>KT-939 raw material<\/td><\/tr>
Product Category<\/strong><\/td>Functional special-purpose cosmetics (whitening\/spot-removing)<\/td><\/tr>
Geographic Scope<\/strong><\/td>Mainland China<\/td><\/tr>
Signing Date<\/strong><\/td>12\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Collaboration Scope<\/h2>\n\n\n\n
Responsibility<\/th>Kintor Pharmaceutical<\/th>Fonow Medicine<\/th><\/tr><\/thead>
Raw Material<\/strong><\/td>Supply KT-939 API; technical improvements<\/td>\u2014<\/td><\/tr>
Product Development<\/strong><\/td>End-product formulation support<\/td>Whitening\/spot-removing cosmetic development<\/td><\/tr>
Registration<\/strong><\/td>Dossier support<\/td>China cosmetic regulatory filing (NMPA)<\/td><\/tr>
Manufacturing<\/strong><\/td>\u2014<\/td>Production of finished cosmetics<\/td><\/tr>
Commercialization<\/strong><\/td>\u2014<\/td>Exclusive sales and marketing rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Strategic Rationale<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
China Cosmetic Market<\/strong><\/td>RMB 500+ billion annually<\/strong>; functional cosmetics (whitening, anti-aging) fastest-growing segment at 15\u201320% CAGR<\/strong><\/td><\/tr>
Melasma Prevalence<\/strong><\/td>Affects ~30% of Asian women<\/strong>; high demand for safe, effective depigmentation solutions<\/td><\/tr>
Folimei Cream Positioning<\/strong><\/td>Fonow’s existing melasma franchise provides established dermatology channel and patient trust<\/td><\/tr>
KT-939 Differentiation<\/strong><\/td>Novel active ingredient vs. established agents (hydroquinone, arbutin, vitamin C derivatives); potential for superior efficacy\/safety profile<\/strong><\/td><\/tr>
Kintor Diversification<\/strong><\/td>Expands beyond core androgen receptor (AR) antagonist pipeline (proxalutamide) into consumer health\/cosmetic dermatology<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n